Targeting SARS-CoV-2 and host cell receptor interactions.

Authors:
Lim SP.

Journal:
Antiviral Res

Publication Year: 2022

DOI:
10.1016/j.antiviral.2022.105514

PMCID:
PMC9792186

PMID:
36581047

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Antiviral Res

Abbreviation: Antiviral Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Driouich JS; Bernadin O; Touret F and 2 more (2023) - Transparency Score: 3/6
Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in pri…
Dsouza L; Pant A; Offei S and 5 more (2023) - Transparency Score: 3/6
Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to…
Dichtl S; Diem G; Jäger M and 11 more (2023) - Transparency Score: 3/6
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolat…
Nguyen HT; Chesnokov A; De La Cruz J and 13 more (2023) - Transparency Score: 3/6
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic p…
Vanhulle E; Doijen J; Stroobants J and 5 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025